MELI vs MRK: Which Is the Better Buy?
Side-by-side comparison of MercadoLibre, Inc. and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
MercadoLibre, Inc. · Consumer Cyclical
$1,635.15
+45.0% upside to fair value
Grade B
High Quality
VS
Merck & Co., Inc. · Healthcare
$113.87
-12.1% upside to fair value
Grade D
High Quality
QuantHub Verdict
MELI has more upside to fair value
(+45.0%).
MRK trades at a lower forward P/E
(32.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MELI |
MRK |
| Current Price |
$1,635.15 |
$113.87 |
| Fair Value Estimate |
$2,370.97 |
$100.14 |
| Upside to Fair Value |
+45.0%
|
-12.1%
|
| Market Cap |
$82.9B |
$281.2B |
| Forward P/E |
43.2x
|
32.0x
|
| EV / EBITDA |
27.0x
|
17.3x
|
| Price / Sales |
2.6x
|
4.3x
|
| Price / FCF |
7.7x
|
19.9x
|
| Revenue Growth YoY |
+49.0%
|
+4.3%
|
| Gross Margin |
43.9%
|
75.9%
|
| Operating Margin |
9.6%
|
27.6%
|
| Return on Equity |
29.6%
|
17.9%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
12.92%
|
5.02%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
MercadoLibre is a leading Latin American e-commerce and fintech platform with a durable competitive moat driven by its integrated logistics and financial services stack. The company commands approximately 30 to 35 percent market share in e-commerce and over 30 percent in online payments in key markets like Brazil. It is founder-influenced with a long-tenured management team and reinvests heavily …
Merck & Co., Inc. is a leading global healthcare company specializing in pharmaceuticals, vaccines, and animal health products. Its business quality is high, supported by a durable competitive moat anchored in the dominant global position of Keytruda in PD-1/PD-L1 oncology, a strong vaccines portfolio including Gardasil, and scale in R&D and manufacturing. The company benefits from a seasoned lea…
Accumulation Zones
| Metric |
MELI |
MRK |
| Zone Low |
$1,778.23 |
$75.11 |
| Zone High |
$2,015.32 |
$85.12 |
| In Buy Zone? |
Yes
|
No
|